Angstrom6
CAS No. 220334-14-5
Angstrom6( —— )
Catalog No. M34159 CAS No. 220334-14-5
Angstrom6 (A-6 peptide) is an 8 amino acid peptide derived from single chain urokinase fibrinogen activator (scuPA) that interferes with the uPA/uPAR cascade and abrogates the downstream effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 74 | Get Quote |
|
| 5MG | 116 | Get Quote |
|
| 10MG | 188 | Get Quote |
|
| 25MG | 319 | Get Quote |
|
| 50MG | 475 | Get Quote |
|
| 100MG | 662 | Get Quote |
|
| 500MG | 1332 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAngstrom6
-
NoteResearch use only, not for human use.
-
Brief DescriptionAngstrom6 (A-6 peptide) is an 8 amino acid peptide derived from single chain urokinase fibrinogen activator (scuPA) that interferes with the uPA/uPAR cascade and abrogates the downstream effects.
-
DescriptionAngstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling.
-
In Vitro——
-
In VivoAnimal Model:C57Bl/6 mice (bearing B16-F10 cells)Dosage:100 mg/kg Administration:S.c.; twice a day for 11 days Result:Reduced the number of lung nodules and reduced the number of lung metastases to 50% of control.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPAI-1
-
RecptorPAI-1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number220334-14-5
-
Formula Weight910.97
-
Molecular FormulaC39H62N10O15
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (109.77 mM; Ultrasonic )H2O : ≥ 100 mg/mL (109.77 mM)
-
SMILESCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(N)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ghamande SA, et al. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008;111(1):89-94.?
molnova catalog
related products
-
Fer and FerT inhibit...
Fer/FerT kinase inhibitor.
-
9'''-Methyllithosper...
9'''-Methyl salvianolate B is a methanolic extract of Cynoglossum columnae Ten. plants.
-
Tiplaxtinin
Tiplaxtinin(PAI-039) is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 uM.
Cart
sales@molnova.com